Clinical data | |
---|---|
Trade names | Coversyl, Coversum, Aceon |
AHFS/Drugs.com | Monograph |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 24% |
Protein binding | 20% |
Metabolism | Kidney |
Elimination half-life | 1–17 hours for perindoprilat (active metabolite) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.120.843 |
Chemical and physical data | |
Formula | C19H32N2O5 |
Molar mass | 368.474 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Perindopril is a medication used to treat high blood pressure, heart failure, or stable coronary artery disease.[2] As a long-acting ACE inhibitor, it works by relaxing blood vessels and decreasing blood volume. As a prodrug, perindopril is hydrolyzed in the liver to its active metabolite, perindoprilat. It was patented in 1980 and approved for medical use in 1988.[3]
Perindopril is taken in the form of perindopril arginine (with arginine, brand names include Coversyl, Coversum) or perindopril erbumine (with erbumine (tert-Butylamine), brand name Aceon). Both forms are therapeutically equivalent and interchangeable,[4] but the dose prescribed to achieve the same effect differs between the two forms.
In Australia, it was one of the top 10 most prescribed medications between 2017 and 2023.[5]